Physician profile
Mark Abate
NPI 1588778674
$15,652.87
in general payments reported to CMS, 2019-2025
52 companies · $2,823 in 2025
The $2,823 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,094 · 2020: $484 · 2021: $396 · 2022: $2,010 · 2023: $2,693 · 2024: $4,152 · 2025: $2,823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,137 · Long Term Medical Supply Or Device Loan: $1,263 · Gift: $880 · Education: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,136.73 |
| Long Term Medical Supply Or Device Loan | $1,263.36 |
| Gift | $880.00 |
| Education | $388.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,662.00 | 2019-2025 | Carvykti, Tecvayli, Darzalex |
| Novartis Pharmaceuticals Corporation | $1,605.11 | 2019-2025 | |
| Sekisui Diagnostics LLC | $1,305.00 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,118.35 | 2019-2025 | Opdivo, Reblozyl, Pomalyst |
| Astellas Pharma US INC | $923.92 | 2019-2025 | Vyloy, Xtandi, Xospata |
| Astrazeneca Pharmaceuticals Lp | $845.02 | 2019-2025 | Enhertu, Lynparza, Calquence |
| Alexion Pharmaceuticals, INC. | $737.94 | 2019-2024 | Ultomiris |
| Lilly USA, LLC | $621.07 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Abbvie INC. | $609.16 | 2019-2024 | Venclexta |
| Gilead Sciences, INC. | $473.16 | 2022-2025 | Trodelvy |
| Emd Serono, INC. | $421.58 | 2023-2025 | Tepmetko |
| Pfizer INC. | $396.71 | 2019-2025 | |
| Incyte Corporation | $326.15 | 2019-2024 | Jakafi |
| Seagen INC. | $322.72 | 2020-2023 | Adcetris |
| Eisai INC. | $306.98 | 2019-2023 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Abate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.